Authorship note: jmz and dta contributed equally to this work. conflict of interest: ad and hsl have submitted a patent application, “inhibiting angiotensinogen to attenuate aortic pathology in marfan syndrome,” for use of antisense oligonucleotides (asos) targeting against angiotensinogen (agt) in aortic aneurysmal disease. aem is an employee of ionis pharmaceuticals, who provided the agt aso. ionis pharmaceuticals did not provide funding for this study

HIGHLIGHTS

• who: LRP and collaborators from the Center for VascularUniversity of of Medicine, Baltimore, Maryland, USA have published the Article: Authorship note: JMZ and DTA contributed equally to this work. Conflict of interest: AD and HSL have submitted a patent application, u201cInhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome,u201d for use of antisense oligonucleotides (ASOs) targeting against angiotensinogen (AGT) in aortic aneurysmal disease. AEM is an employee of Ionis Pharmaceuticals, who provided the AGT ASO. Ionis Pharmaceuticals did not provide funding for this study, in the Journal: (JOURNAL) of August/23,/2022
• what: The . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.